Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Capital Expenditures (2016 - 2025)

Veracyte (VCYT) has disclosed Capital Expenditures for 14 consecutive years, with -$3.6 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 133.43% to -$3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, down 79.55% year-over-year, with the annual reading at $2.3 million for FY2025, 79.55% down from the prior year.
  • Capital Expenditures hit -$3.6 million in Q4 2025 for Veracyte, down from $5.4 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $10.7 million in Q4 2024 to a low of -$3.6 million in Q4 2025.
  • Historically, Capital Expenditures has averaged $1.4 million across 5 years, with a median of $509500.0 in 2021.
  • Biggest YoY gain for Capital Expenditures was 16746.67% in 2023; the steepest drop was 454.58% in 2023.
  • Year by year, Capital Expenditures stood at $841000.0 in 2021, then plummeted by 101.78% to -$15000.0 in 2022, then surged by 16746.67% to $2.5 million in 2023, then skyrocketed by 329.92% to $10.7 million in 2024, then tumbled by 133.43% to -$3.6 million in 2025.
  • Business Quant data shows Capital Expenditures for VCYT at -$3.6 million in Q4 2025, $5.4 million in Q3 2025, and -$472000.0 in Q2 2025.